A small dose of botulinum toxin A is effective for treating androgenetic alopecia in Chinese patients

Zhang, Li; Yu, Qian; Wang, Yao; Ma, Yanyan; Shi, Yu; Li, Xiuli

doi:10.1111/dth.12785

Cited by 26 publications

(38 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar study with the same results was conducted by Singh in 2017 [171]. Compared to his predecessors, Zhang [172] experimented a lower dosage of BoNT-A for male androgenetic alopecia in an open label study in 2019. Among 24 patients treated with 50 U of toxin, after 6 months of treatment, 11 patients showed significant hair regrowth (>10% from baseline), 8 showed minimal improvement, and 5 had no changes.…”

Section: Androgenetic Alopeciasupporting

confidence: 55%

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Martina

Diotallevi

Radi

et al. 2021

Toxins

View full text Add to dashboard Cite

Botulinum toxin is a superfamily of neurotoxins produced by the bacterium Clostridium Botulinum with well-established efficacy and safety profile in focal idiopathic hyperhidrosis. Recently, botulinum toxins have also been used in many other skin diseases, in off label regimen. The objective of this manuscript is to review and analyze the main therapeutic applications of botulinum toxins in skin diseases. A systematic review of the published data was conducted, following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Botulinum toxins present several label and off-label indications of interest for dermatologists. The best-reported evidence concerns focal idiopathic hyperhidrosis, Raynaud phenomenon, suppurative hidradenitis, Hailey–Hailey disease, epidermolysis bullosa simplex Weber–Cockayne type, Darier’s disease, pachyonychia congenita, aquagenic keratoderma, alopecia, psoriasis, notalgia paresthetica, facial erythema and flushing, and oily skin. Further clinical trials are still needed to better understand the real efficacy and safety of these applications and to standardize injection and doses protocols for off label applications.

show abstract

Section: Androgenetic Alopeciasupporting

confidence: 55%

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Martina

Diotallevi

Radi

et al. 2021

Toxins

View full text Add to dashboard Cite

show abstract

“…Possibly, BTA may relax the muscles around the head, increase blood flow and oxygen concentration in the alopecia area, and further inhibit the activation of DHT, ultimately leading to a reduced occurrence of hair loss. Moreover, a high concentration of oxygen can stimulate the hair follicle into the growth phase, resulting in hair regeneration [ 25 – 27 ]. In the present study, we demonstrated that the treatment of the alopecia region with BTA significantly increased hair counts of patients with AGA, and the effect of BTA alone was lower compared to that of BTA combined with FNS.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and Safety of Botulinum Toxin Type A in the Treatment of Androgenetic Alopecia

Zhou¹,

Yu²,

Zhao³

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Background. Androgenetic alopecia (AGA) represents the most frequent clinical complaint encountered by dermatologists and is characterized by a progressive miniaturization of the hair follicle. However, the efficacy and safety of current medical treatment remain limited, and more personalized therapeutic approaches for AGA are needed. Therefore, the present study is aimed at investigating the efficacy and safety of botulinum toxin type A (BTA) in patients with AGA. Methods. 63 patients with AGA meeting the inclusion criteria were included in this study and treated with BTA injection or BTA injection combined with oral finasteride (FNS). In the scalp, 30 sites were injected with 100 U of BTA in each site and patients received BTA after every 3 months for a total of 4 times. Hair counts, head photographs, evaluation scores, and self-assessment were assessed in patients with AGA. Results. Hair counts in both groups at all time points were significantly higher as compared with those before treatment. After 4 times of treatment, hair counts in the BTA+FNS group were higher than those in the BTA group. Hair growth and density were significantly augmented, and the area of hair loss was attenuated after each treatment as revealed by head photographs. The effective rates of BTA and BTA+FNS groups were 73.3% and 84.8%, respectively, following 4 times treatment. Conclusion. BTA is a safe and effective therapeutic strategy for the treatment of AGA without adverse effects, and BTA combined with FNS exhibited a superior therapeutic effect than BTA alone.

show abstract

“…8 patients of 10 have good response toward the therapy in Sehdev Singh and colleagues’ research 21 . 9 of 24 patients showed obvious hair regrowth, 10 of 24 without apparent hair growth and 5 of 24 showed hair loss in Li Zhang and colleagues’ pilot study 22 . In addition, Hee‐Ryung Cho and colleagues in 2010 provided contrary evidence and only one of seven patients have spontaneously hair growth of positive outcomes 18 .…”

Section: Discussionmentioning

confidence: 99%

“…21 9 of 24 patients showed obvious hair regrowth, 10 of 24 without apparent hair growth and 5 of 24 showed hair loss in Li Zhang and colleagues' pilot study. 22 In addition, Hee-Ryung Cho and colleagues in 2010 provided contrary evidence and only one of seven patients have spontaneously hair growth of positive outcomes. 18 These results were consecutive to some extent and may reflect the possibility that patients with heterogeneous conditions of disease type, dilution and dosing, injection procedures, and product of botulinum toxin type A will have a complete contrary response.…”

Section: Discussionmentioning

confidence: 99%

Botulinum toxin as a double‐edged sword in alopecia: A systematic review

Wang

Zhang

Zheng

et al. 2020

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background Alopecia is a common disease influencing the quality of life of the patients. Botulinum toxin has been widely employed in cosmetic dermatology and was applied in some clinical trials to treat alopecia. Aims Hence, We conducted a systematic review to examine the safety and efficacy of using botulinum toxin in treating alopecia. Methods Cochrane Library, Embase, PubMed, and Web of Science databases were used to search for articles. A PICOS question was formed and the author, year of publication, number of participants, study design, product, dilution and dosing, outcome measurement, findings, side effects, and follow‐up were retrieved. The Oxford Centre for Evidence‐Based Medicine 2011 Levels of Evidence was used as a qualitative indicator to evaluate the levels of evidence. Results Eleven articles published between 2005 and 2019 were included. 9 of which were about treatment effects and 2 were concerning adverse effects. The total number of the participants was 106, and the number for each article was ranged from 1 to 50. Varying type of outcome measurements was used for the publications. 8 articles were evaluated as Level 4 and 1 was evaluated as Level 5 during the 9 articles with treatment effects. Conclusions The results showed that botulinum toxin may function as a double‐edged sword and have a low degree of efficacy and safety in treating alopecia. The study may be useful to remind the physicians of adverse effects in clinical practice and pave the way for further research. A larger, randomized, placebo‐controlled study is warranted.

show abstract

A small dose of botulinum toxin A is effective for treating androgenetic alopecia in Chinese patients

Cited by 26 publications

References 6 publications

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Effectiveness and Safety of Botulinum Toxin Type A in the Treatment of Androgenetic Alopecia

Botulinum toxin as a double‐edged sword in alopecia: A systematic review

Contact Info

Product

Resources

About